Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 7, 2011 Brandon Glenn	"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors.
The Motley Fool September 2, 2009 Brian Orelli	Should You Buy This Spinoff? Cardinal Health kicks its baby out of the nest.
The Motley Fool August 3, 2006 Ryan Fuhrmann	Cardinal Distributes the Goods The drug wholesaler and distributor has to regain investor confidence and rebuild a track record in a changed industry. So far, so good for 2006. Let's see if any further information can be found once Cardinal submits its 10-K filing to the SEC.
The Motley Fool October 28, 2004 Brian Gorman	Cardinal's Good News: No News The drug wholesaler took a major step toward rehabilitating itself with the release of its 10-K.
The Motley Fool January 30, 2006 Brian Gorman	Cardinal Inches Higher The distribution is looking healthier, but Cardinal Health still has work to do. Investors, take note.
The Motley Fool July 1, 2004 W.D. Crotty	Drug Wholesalers Taking a Beating A sharp drop at drug wholesaler Cardinal Health provides a unique buying opportunity.
The Motley Fool May 20, 2004 Tom Taulli	Cardinal Rules of M&A Cardinal Health is upbeat on its latest acquisition, but needs bigger deals to push growth.
The Motley Fool November 7, 2007 Billy Fisher	Cardinal Has Its Wings Clipped Despite a healthy year-over-year pop of 15% in EPS from operations, much of the focus in the first-quarter was shifted to a weak performance by Cardinal's pharmaceutical services segment.
The Motley Fool September 12, 2007 Brian Orelli	Fitting Fission at Abraxis BioScience Abraxis BioScience will split itself into a biotech firm and a generic drug business. Both new companies stand to benefit, but will investors?
The Motley Fool June 28, 2005 Brian Gorman	Cardinal Changes Course The health care company's warning is a disappointment, but the firm's new focus on returning cash to shareholders is far from bad news.
The Motley Fool August 24, 2011 Brandon Glenn	Cardinal Health Sees Opportunity (but Faces Challenges) in Specialty Drugs Is Cardinal up for the challenge?
The Motley Fool June 13, 2006 Ryan Fuhrmann	Cardinal Looks to Deliver Cardinal Health has been through a tumultuous couple of years but appears to have weathered company-specific and industry storms. If the drug distributor can meet its long-term goals, then its stock should represent a long-term solid investment.
The Motley Fool January 26, 2007 Billy Fisher	A Clean Bill of Health at Cardinal Good results and a key divestiture have this health care company rolling. Investors, take note.
BusinessWeek November 24, 2003 Roger O. Crockett	Cardinal Health, Heal Thyself CEO Walter aims to revive growth, selling high-tech gear and expanding overseas.
The Motley Fool October 6, 2008 Brian Orelli	Cardinal Atones for Its Sins The drugmaker gets its licenses to distribute controlled substances reinstated.
The Motley Fool May 6, 2008 Steven Renaldi	McKesson Garners Generic Growth New products offer the generic-drug distributor profit potential in a competitive industry.
The Motley Fool January 18, 2005 Brian Gorman	Cardinal Doesn't Get Ruffled The drug distributor's potential loss of Japanese pharmaceutical Eisai will hurt in the short term, but fortunately for investors Cardinal Health continues to plan wisely.
The Motley Fool August 5, 2005 Stephen D. Simpson	Can This Cardinal Sing? If Cardinal Health succeeds in its plans to return more capital to shareholders, this could become an interesting income play. This stock is worth keeping an eye on for the future.
The Motley Fool October 8, 2007 Billy Fisher	McKesson Expands Its Empire A new acquisition strengthens the company's presence in the cancer drug market. Investors, take note.
The Motley Fool May 2, 2008 Steven Renaldi	Cardinal Health Gets Its Nest in Order Share price rises as investors hope the company is beginning to put some of its troubles behind it.
The Motley Fool March 23, 2011 Jordan DiPietro	Should You Buy and Hold Cardinal Health? Does this company have the traits of a good retirement stock?
The Motley Fool April 4, 2007 Toby Shute	Bullish on a Brink's Breakup Another hedge fund is urging The Brink's Company to break up with -- itself. Is this an opportunity for investors?
The Motley Fool April 18, 2008 Brian Orelli	Recalls Can't Beat Baxter In spite of charges for two recalls, Baxter posts a decent quarter.
Chemistry World March 3, 2015 Phillip Broadwith	J&J to sell cardiac devices to wholesaler Cardinal Johnson & Johnson has agreed to sell its cardiovascular surgical devices subsidiary, Cordis, to wholesale supplier Cardinal Health.
The Motley Fool March 30, 2011 Brian Orelli	How to Play the Pfizer Breakup (If It Happens) The sum of the parts could be worth more than the whole.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool January 5, 2010 Brian Orelli	A Deal Manufactured by Necessity Genzyme gets some help from a new friend.
The Motley Fool October 12, 2009 Robert Steyer	Healthy Spinoffs, Happy Investors When medical companies spin off unwanted divisions, the spinoffs can outperform the parent.
The Motley Fool September 27, 2007 Billy Fisher	Baxter Looking to Bounce Back Shares of the medical device maker finally rebound following a company recall of infusion pumps.
The Motley Fool December 10, 2004 Brian Gorman	Cardinal Picks a Lilly Cardinal Health's deal with Lilly suggests the new fee-for-service model is gaining traction.
The Motley Fool September 24, 2008 Brian Orelli	Hey, You! Stop! The FDA has ordered Baxter and Hospira to stop making their ophthalmic balanced salt solutions within 60 days.
The Motley Fool February 28, 2011 Brian Orelli	Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on.
The Motley Fool July 28, 2004 Brian Gorman	Cardinal Watching Cardinal Health continues to be pummeled, but wait patiently, because a buying opportunity could emerge.
The Motley Fool October 26, 2005 Stephen D. Simpson	Cardinal's Tweet More Sweet Changes at the giant manufacturer, distributor, and service provider in the health-care industry are working out well, but the stock price already reflects it.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool May 6, 2005 W.D. Crotty	McKesson's New Pep Pill The drug wholesaler reports strong fourth-quarter results as it moves to a fee-for-service model.
The Motley Fool August 10, 2006 Stephen D. Simpson	Volatility, Thy Name Is Hospira Margins continue to stand in the way of consistent performance at the health-care company. Investors, take note.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool June 2, 2005 Brian Gorman	Hospira's Little Purchase There may be more to Hospira's recent acquisition than meets the eye.
Chemistry World March 2011	Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool September 9, 2011 Brandon Glenn	Cardinal Health Looks to PET Drugs to Drive Margins The nuclear medicine business is an important driver of higher margins for the drug distribution company.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
The Motley Fool August 30, 2007 Billy Fisher	Altria Continues Its Breakup Altria announces its plan to spin-off Phillip Morris International. Investors, this news should be viewed as an encouraging step.
The Motley Fool March 30, 2011 Sean Williams	China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool September 23, 2011 Jim Royal	3 Special Situations You'll Want to Watch Closely These breakups look likely to provide great value.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool November 8, 2011 Brandon Glenn	Cardinal Health Looks to Build China Business, but Has Long Way to Go For pharmaceuticals distributor Cardinal Health, China represents a world of opportunity.
The Motley Fool January 21, 2005 Rich Duprey	Cardinal Back in the Nest Drug distributor and Japanese pharma Eisai come to agreement after all.